See the DrugPatentWatch profile for Sensipar
How does Sensipar work in the body?
Sensipar (cinacalcet) lowers blood calcium by making the parathyroid glands release less parathyroid hormone (PTH). It does this by acting as a calcimimetic: it increases the sensitivity of the calcium-sensing receptor (CaSR) on parathyroid chief cells to extracellular calcium. As a result, the parathyroid glands interpret the same calcium level as “enough,” so PTH secretion drops and serum calcium falls. [1]
What does the drug change—PTH first, then calcium?
Cinacalcet’s immediate pharmacologic effect is reduced PTH release. With lower PTH, downstream calcium levels decrease because PTH normally increases serum calcium through its effects on calcium release and reabsorption processes. [1]
Why is this useful for conditions like hyperparathyroidism?
In diseases where PTH is elevated (or where calcium control is difficult), lowering PTH helps normalize calcium levels. Cinacalcet is used to manage hypercalcemia related to parathyroid hormone dysregulation, including secondary hyperparathyroidism in people with chronic kidney disease. [1]
What receptor pathway is involved?
The key mechanism involves the calcium-sensing receptor (CaSR) on the parathyroid gland. Cinacalcet acts allosterically as a calcimimetic to enhance CaSR signaling, which suppresses PTH secretion. [1]
Are there downstream effects patients might notice from lowering calcium?
Because the goal is to reduce serum calcium, adverse effects can relate to hypocalcemia risk. Lower calcium can lead to symptoms such as tingling or numbness, muscle cramps, or spasms in some patients, reflecting the physiologic consequence of PTH suppression and calcium lowering. [1]
Sources
[1] U.S. Food and Drug Administration (FDA). Sensipar (cinacalcet) Prescribing Information. https://www.accessdata.fda.gov/